A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Trial Profile

A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs Hyaluronidase (Primary) ; Atezolizumab; Cisplatin; Gemcitabine
  • Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 12 Jul 2018 Planned End Date changed from 1 Jun 2020 to 1 Feb 2020.
    • 12 Jul 2018 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2019.
    • 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top